A Survey on the Management of HR+/HER2- mBC

About the Survey

This survey will provide insights into the approaches taken by community or academic oncologists such as yourself in managing cases with HR+/HER2- mBC. The feedback will be utilized to guide in the development of the consensus-derived manuscript and abstracts.

This survey will focus on the following areas:

Understanding of your general clinical practice and the key factors that play a role in your clinical practice decisions
Use of biomarker testing
First-line treatment decisions for HR+/HER2- mBC
Second-line treatment decisions for HR+/HER2- mBC
Decisions regarding subsequent-line therapy
Management and monitoring of toxicities

Registration

Click the “Register” button below and please provide the information required.

After registration, you will receive a confirmation email with instructions on accessing and completing the survey.

ATTENDEE INFORMATION

First NameLast NameEmail Address

PROFILE INFORMATION

HospitalJob Title/RoleMobile/Cellphone (Include Country Code)Are you a Licensed Oncologist?YesDo you treat patients with HR+/HER2- mBC?YesNo

ADDRESS INFORMATION

Business / Practice AddressAddressCityState/ProvinceZIP/Postal Code

CONSENT

I agree that eScientiq may use my email address to send me information related to this event. I understand that my details will not be used in any other context or for any other purpose.I agree that eScientiq may contact me via the above contact details to ask for my feedback about this meeting.I confirm that my email provided above may be used by eScientiq to send an Amazon gift card.I agree that eScientiq may communicate with me via electronic means for the purposes of sending me offers for future collaborations, participation in scientific meetings, promotional events, as well as participation in surveys and activities. Your consent is completely voluntary and can be withdrawn at anytime on info@escientiq.com

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.